论文部分内容阅读
利用甲胎蛋白（ＡＦＰ）和ａ－Ｌ－岩藻糖苷酶（ＡＦＵ）联合检测各种肝病及肝脏外恶性肿瘤患者１３５例，正常人３００例；对６例肝癌患者术前、术后ＡＦＰ和ＡＦＵ进行动态观察。结果显示原发性肝癌（ＰＨＣ）术前、术后ＡＦＰ和ＡＦＵ水平的变化对肝癌手术切除彻底性的明确，治疗效果的评价及预后判断有一定意义。ＡＦＰ和ＡＦＵ检测在除ＰＨＣ外的其它肝脏疾病中也有少部分呈阳性表达。正常人ＡＦＰ呈用性。ＡＰＵ在ＰＨＣ与其它肝病有显著性差别。提示ＡＦＰ和ＡＦＵ联合检测能提高ＰＨＣ的检出率和早期肝癌的发现，有着评价ＰＨＣ术后疗效、判断预后的价值。
AFP and a-L-fucosidase (AFU) were used to jointly detect 135 cases of liver diseases and extrahepatic malignancies and 300 cases of normal persons; and preoperative and postoperative AFP and 6 cases of liver cancer patients. AFU performs dynamic observations. The results showed that the changes of preoperative and postoperative AFP and AFU levels in primary liver cancer (PHC) have certain significance for the completeness of surgical resection of hepatocellular carcinoma, evaluation of therapeutic effect and prognosis. The AFP and AFU tests also showed a few positive expression in liver diseases other than PHC. AFP is normal for normal people. APU is significantly different from other liver diseases in PHC. It is suggested that combined detection of AFP and AFU can increase the detection rate of PHC and the early detection of liver cancer, and it has the value of evaluating the efficacy of PHC after operation and predicting the prognosis.